Jun 22, 2026 08:30AM
Jun 15, 2026 03:00AM
Jun 12, 2026 06:44PM
Jun 12, 2026 02:03PM
Jun 2, 2026 08:02AM
Jun 1, 2026 08:01AM
Jun 1, 2026 08:00AM IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) combined with lenvatinib and TACE reduced the risk of disease progression or death by 30% in embolization-eligible unresectable liver cancer in
May 28, 2026 09:18PM
May 28, 2026 12:42PM
May 27, 2026 04:04AM
May 22, 2026 10:17AM
May 22, 2026 10:16AM
May 22, 2026 09:30AM
May 22, 2026 09:30AM Datroway® Approved in the U.S. as First TROP2 Directed Antibody Drug Conjugate for First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer Who Are Not PD-1/PD-L1 Inhibitor Cand
May 22, 2026 08:00AM
May 22, 2026 08:00AM
May 22, 2026 07:00AM
May 22, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 07:00AM
May 18, 2026 05:07AM AstraZeneca receives FDA approval for hypertension drug Baxfendy
May 15, 2026 09:52PM
May 15, 2026 06:31PM
May 14, 2026 07:00AM
May 1, 2026 05:44AM
Apr 30, 2026 09:42PM
Apr 30, 2026 11:49AM
Apr 28, 2026 01:46PM AstraZeneca, Amgen partner with FDA to test real-time AI trial monitoring
Apr 28, 2026 07:03AM
Apr 28, 2026 07:00AM
Apr 27, 2026 07:03AM
Apr 27, 2026 07:00AM
Apr 20, 2026 07:01AM
Apr 7, 2026 02:09PM
Apr 2, 2026 07:00AM AstraZeneca's IMFINZI and IMJUDO combination shows progression benefit in liver cancer
Apr 2, 2026 07:00AM
Mar 24, 2026 10:30AM
Mar 9, 2026 08:45AM
Mar 9, 2026 07:00AM
Mar 9, 2026 02:30AM
Feb 20, 2026 07:01AM
Feb 20, 2026 07:00AM CALQUENCE® plus venetoclax approved in the US as first all-oral, fixed-duration combination for patients with chronic lymphocytic leukemia in the 1st-line setting
Feb 19, 2026 05:28AM
Feb 19, 2026 02:30AM
Feb 3, 2026 07:00AM
Feb 3, 2026 07:00AM
Feb 3, 2026 04:11AM
Feb 3, 2026 02:30AM
Jan 19, 2026 02:30AM ENHERTU® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Jan 13, 2026 07:00AM

325,226 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All